23 May 2012, Munich – Thirteen European technology transfer organizations and a guest partner from Canada were the joint organizers of BioVaria, which took place last week in Munich for the fifth year running. The feedback from organizers and participants alike was extremely positive: in the five years since Ascenion launched BioVaria, the conference has become a leading marketplace for life-science inventions from European public research institutes and universities.
This year, 46 institutes from nine countries presented numerous licensable projects, in particular new approaches to the treatment of cancer, inflammation and cardiovascular and autoimmune disease.
The event met with a lively response from the biopharmaceutical industry, and both the presentations and the exhibition area were well attended. A total of 140 delegates from research, industry and technology transfer enjoyed animated discussions on project details and cooperation opportunities.
“I have experienced BioVaria 2012 as a valuable forum where selected projects from academia are presented to potential partners for commercialization. The opportunity to network in this framework was much appreciated,” Dr Thomas Hanke, Sourcing Director at Novo Nordisk, commented.
The number of participants from industry has been climbing steadily since the first BioVaria in 2007, and there are now an impressive number of major players among the sponsors.
“This shows that by pulling together technology offers across organizational, regional and national boundaries, we are successfully reaching our target group of potential licensees from industry,” said Dr Christian Stein, CEO of Ascenion. “BioVaria therefore makes an important contribution to our common goal: using the results of publicly funded research for the benefit of all.”
The next BioVaria will take place on 4 June 2013.
About BioVaria
BioVaria is jointly organized by Ascenion and numerous technology transfer organizations from all over Europe. The event brings together researchers from academia, industry representatives and investors, providing an ideal environment to make contact and initiate partnerships for developing promising early-stage projects.
BioVaria at a glance:
- Comprehensive overview of licensing and investment opportunities arising from publicly funded research in Europe
- Focus on licensable, patent-protected technologies, materials, diagnostics and therapeutics in fields such as cancer, inflammation, cardiovascular and autoimmune disease
- Presentation of 50 technologies
- Innovative format combining 10-minute oral presentations with an all-day poster exhibition
- An opportunity to discuss projects face-to-face with the leading scientists
Partners of this year‘s BioVaria:
European technology transfer partners: Ascenion GmbH, Austria Wirtschaftsservice Gesellschaft mbH, Bayerische Patentallianz GmbH, BDC - The Business Development Company GmbH, BTO - Bergen Teknologioverføring AS, EMBLEM Technology Transfer GmbH, FIST S.A. (France Innovation Scientifique & Transfert), IPAL GmbH, KU Leuven Research & Development (LRD), Max Planck Innovation GmbH, National Genome Research Network, PROvendis GmbH, Tecnalia Research & Innovation
Guest partner from Canada: University of Manitoba’s Technology Transfer Office (TTO)
Sponsors: BioM, Bayer Healthcare, Boehringer Ingelheim, Bachem AG, Hertin - IP Law Firm, MSD, Novo Nordisk, Sanofi, Vossius & Partner
Patron: Bavarian Ministry of Economic Affairs, Infrastructure, Transport and Technology
Media: Going Public Magazin, Innovaro Pharmalicensing, transkript
Communication: KONOCOM
About Ascenion GmbH
Ascenion GmbH is an IP asset management company focused on the life sciences. Ascenion advises and supports public research institutions with regard to the protection and exploitation of their intellectual property (patents, knowledge, materials), and initiates and mediates license agreements between research institutions and industry. The company places particular emphasis on coaching company founders and on active equity management. Ascenion was founded in 2001 as a 100% subsidiary of the Life-Science Foundation for the Promotion of Science and Research and has since acquired 23 research institutes in the Helmholtz and Leibniz Associations, together with the Hanover Medical School and the research institute TWINCORE as exclusive partners. Ascenion currently markets around 750 technologies on behalf of these institutes and closes an average of about 70 agreements between research and industry per year. The team has also coached numerous spin-offs through their foundation and early growth, and Ascenion holds equity in 25 of these companies. Ascenion’s headquarters are in Munich, with further offices in Berlin, Braunschweig, Hamburg, Hanover and Neuherberg. Further information available at <link http: www.ascenion.de external-link-new-window>www.ascenion.de
